WO2012091153A3 - Orally disintegrating tablet - Google Patents

Orally disintegrating tablet Download PDF

Info

Publication number
WO2012091153A3
WO2012091153A3 PCT/JP2011/080568 JP2011080568W WO2012091153A3 WO 2012091153 A3 WO2012091153 A3 WO 2012091153A3 JP 2011080568 W JP2011080568 W JP 2011080568W WO 2012091153 A3 WO2012091153 A3 WO 2012091153A3
Authority
WO
WIPO (PCT)
Prior art keywords
fine granules
active ingredient
pharmaceutically active
lansoprazole
controlled release
Prior art date
Application number
PCT/JP2011/080568
Other languages
French (fr)
Other versions
WO2012091153A2 (en
Inventor
Shiro Ishii
Yutaka Ebisawa
Takayuki Okabe
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45509604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012091153(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US13/997,862 priority Critical patent/US20130273157A1/en
Priority to KR1020137019795A priority patent/KR20140007364A/en
Priority to AU2011350396A priority patent/AU2011350396A1/en
Priority to SG2013040944A priority patent/SG190905A1/en
Priority to EA201390981A priority patent/EA028217B1/en
Priority to JP2013529237A priority patent/JP2014501224A/en
Priority to CA2823166A priority patent/CA2823166C/en
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Priority to BR112013014875A priority patent/BR112013014875A2/en
Priority to CN2011800685821A priority patent/CN103402500A/en
Priority to MX2013007588A priority patent/MX2013007588A/en
Priority to EP11811174.9A priority patent/EP2658530A2/en
Publication of WO2012091153A2 publication Critical patent/WO2012091153A2/en
Publication of WO2012091153A3 publication Critical patent/WO2012091153A3/en
Priority to TNP2013000220A priority patent/TN2013000220A1/en
Priority to ZA2013/04617A priority patent/ZA201304617B/en
Priority to CR20130327A priority patent/CR20130327A/en
Priority to MA36063A priority patent/MA34768B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is an orally disintegrating tablet obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules during tableting, and can control the release of lansoprazole for a long time, and can maintain a therapeutically effective concentration for a prolonged time, and shows superior disintegration property in the oral cavity. An orally disintegrating tablet containing (i) fine granules showing controlled release of a pharmaceutically active ingredient, which contains fine granules containing a pharmaceutically active ingredient and a coating layer containing a methacrylic acid/methyl acrylate/methyl methacrylate copolymer, wherein the fine granules containing a pharmaceutically active ingredient are coated with more than 80 wt% and not more than 300 wt% of the copolymer, and (ii) fine granules showing controlled release of a pharmaceutically active ingredient, which contains the pharmaceutically active ingredient and a coating layer comprising (a) an ethyl acrylate/methyl methacrylate copolymer, and (b) one or more kinds of polymers selected from the group consisting of methacrylic acid/ethyl acrylate copolymer, hypromellose phthalate, carboxymethylethylcellulose, polyvinyl acetate phthalate, hydroxypropyl methylcellulose acetate succinate and cellulose acetate phthalate, wherein the fine granules (i) and fine granules (ii) have an average particle size of not more than 500 micrometer, and the pharmaceutically active ingredient is lansoprazole or an optically active form thereof or a salt thereof.
PCT/JP2011/080568 2010-12-27 2011-12-26 Orally disintegrating tablet WO2012091153A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR112013014875A BR112013014875A2 (en) 2010-12-27 2011-12-26 orally disintegrating tablet
CN2011800685821A CN103402500A (en) 2010-12-27 2011-12-26 Orally disintegrating tablet
KR1020137019795A KR20140007364A (en) 2010-12-27 2011-12-26 Orally disintegrating tablet
MX2013007588A MX2013007588A (en) 2010-12-27 2011-12-26 Orally disintegrating tablet.
EA201390981A EA028217B1 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet (variants)
JP2013529237A JP2014501224A (en) 2010-12-27 2011-12-26 Orally disintegrating tablets
CA2823166A CA2823166C (en) 2010-12-27 2011-12-26 Orally disintegrating tablet
US13/997,862 US20130273157A1 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet
EP11811174.9A EP2658530A2 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet
AU2011350396A AU2011350396A1 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet
SG2013040944A SG190905A1 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet
TNP2013000220A TN2013000220A1 (en) 2010-12-27 2013-05-24 Orally disintegrating tablet
ZA2013/04617A ZA201304617B (en) 2010-12-27 2013-06-21 Orally disintegrating tablet
CR20130327A CR20130327A (en) 2010-12-27 2013-06-27 ORAL DISINTEGRATION COMPRESSED
MA36063A MA34768B1 (en) 2010-12-27 2013-06-28 ORODISPERSIBLE TABLET

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061427384P 2010-12-27 2010-12-27
US61/427,384 2010-12-27

Publications (2)

Publication Number Publication Date
WO2012091153A2 WO2012091153A2 (en) 2012-07-05
WO2012091153A3 true WO2012091153A3 (en) 2012-09-07

Family

ID=45509604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/080568 WO2012091153A2 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet

Country Status (23)

Country Link
US (1) US20130273157A1 (en)
EP (1) EP2658530A2 (en)
JP (1) JP2014501224A (en)
KR (1) KR20140007364A (en)
CN (1) CN103402500A (en)
AR (1) AR084610A1 (en)
AU (1) AU2011350396A1 (en)
BR (1) BR112013014875A2 (en)
CA (1) CA2823166C (en)
CL (1) CL2013001793A1 (en)
CO (1) CO6731132A2 (en)
CR (1) CR20130327A (en)
EA (1) EA028217B1 (en)
EC (1) ECSP13012718A (en)
MA (1) MA34768B1 (en)
MX (1) MX2013007588A (en)
PE (1) PE20141115A1 (en)
SG (2) SG190905A1 (en)
TN (1) TN2013000220A1 (en)
TW (1) TW201304823A (en)
UY (1) UY33841A (en)
WO (1) WO2012091153A2 (en)
ZA (1) ZA201304617B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241910B2 (en) 2008-03-11 2016-01-26 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
ES2790358T3 (en) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation
EP3141542B1 (en) 2011-12-28 2020-05-27 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MX2015011448A (en) 2013-03-15 2016-06-06 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin.
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2852054T3 (en) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compounds and their uses for modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
EP3868745A1 (en) 2014-02-07 2021-08-25 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN111704543A (en) 2014-11-14 2020-09-25 燿石治疗公司 Process and intermediates for preparing alpha, omega-dicarboxylic acid terminated dialkyl ethers
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017096230A1 (en) 2015-12-04 2017-06-08 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (en) 2016-05-12 2019-06-21 全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI778983B (en) * 2016-10-12 2022-10-01 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2018209257A1 (en) * 2017-05-11 2018-11-15 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
MX2020000332A (en) 2017-07-10 2020-07-13 Takeda Pharmaceuticals Co Preparation comprising vonoprazan.
CN108576205B (en) * 2018-03-22 2022-01-04 湖北省农业科学院农产品加工与核农技术研究所 Processing method for strawberry combined drying
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
WO2007078271A2 (en) * 2005-12-20 2007-07-12 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1837016A2 (en) * 2006-03-08 2007-09-26 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
EP2098250A1 (en) * 2006-12-28 2009-09-09 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
WO2009113703A2 (en) * 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
US20100015239A1 (en) * 2008-07-17 2010-01-21 Ahmed Salah U Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (en) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
JPH072761B2 (en) 1985-03-20 1995-01-18 不二パウダル株式会社 Microcrystalline cellulose spherical granules and method for producing the same
JPS62277322A (en) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd Stabilized pharmaceutical composition and production thereof
FR2679451B1 (en) 1991-07-22 1994-09-09 Prographarm Laboratoires MULTIPARTICLE TABLET WITH RAPID DELIVERY.
DE69331839T2 (en) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Fast-dissolving tablet and its manufacture
JP2919771B2 (en) 1995-04-17 1999-07-19 佐藤製薬株式会社 Method for producing fast-dissolving tablet and fast-dissolving tablet produced by the method
JPH0948726A (en) 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd Rapidly disintegrating preparation in mouth cavity and its production
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (en) 1996-11-14 2006-10-04 武田薬品工業株式会社 Crystal of 2- (2-pyridylmethylsulfinyl) benzimidazole compound and process for producing the same
CA2323680C (en) 1998-05-18 2007-05-22 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US7399485B1 (en) 1998-07-28 2008-07-15 Takeda Pharmaceutical Company Limited Rapidly Disintegrable solid preparation
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1277752B1 (en) 2000-04-28 2006-11-22 Takeda Pharmaceutical Company Limited Process for producing optically active sulfoxide derivative
DK1293507T3 (en) 2000-05-15 2007-12-27 Takeda Pharmaceutical Process for producing crystals
DK1337525T3 (en) 2000-12-01 2011-09-19 Takeda Pharmaceutical Process for crystallizing (R) - or (S) -lansoprazole
JP4493970B2 (en) 2002-10-16 2010-06-30 武田薬品工業株式会社 Sustained formulation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
WO2007078271A2 (en) * 2005-12-20 2007-07-12 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1837016A2 (en) * 2006-03-08 2007-09-26 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
EP2098250A1 (en) * 2006-12-28 2009-09-09 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
WO2009113703A2 (en) * 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
US20100015239A1 (en) * 2008-07-17 2010-01-21 Ahmed Salah U Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EVONIK INDUSTRIES: "EUDRAGIT FS 30 D", 31 July 2010 (2010-07-31), pages 1 - 3, XP055028678, Retrieved from the Internet <URL:http://web.archive.org/web/20100731192517/http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/enteric-formulations/fs-30-d/Pages/default.aspx> [retrieved on 20120531] *
FLORENCE LECOMTE ET AL: "pH-Sensitive Polymer Blends Used as Coating Materials to Control Drug Release from Spherical Beads: Elucidation of the Underlying Mass Transport Mechanisms", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 22, no. 7, 1 July 2005 (2005-07-01), pages 1129 - 1141, XP019370885, ISSN: 1573-904X, DOI: 10.1007/S11095-005-5421-2 *
SCHMID S ET AL: "ENTERIC COATING OF IBUPROFEN CRYSTALS USING MODIFIED METHACRYLATE COPOLYMERS", DRUGS MADE IN GERMANY, AULENDORF, DE, vol. 44, no. 1, 1 January 2001 (2001-01-01), pages 12 - 19, XP001016138, ISSN: 0012-6682 *
SHIMIZU T ET AL: "FORMULATION STUDY FOR LANSOPRAZOLE FAST-DISINTEGRATING TABLET. II. EFFECT OF TRIETHYL CITRATE ON THE QUALITY OF THE PRODUCTS", CHEMICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 51, no. 9, 1 October 2003 (2003-10-01), pages 1029 - 1035, XP001174705, ISSN: 0009-2363, DOI: 10.1248/CPB.51.1029 *
WAGNER K G ET AL: "Development of disintegrating multiple-unit tablets on a high-speed rotary tablet press", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 50, no. 2, 1 September 2000 (2000-09-01), pages 285 - 292, XP004257203, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(00)00078-3 *

Also Published As

Publication number Publication date
TN2013000220A1 (en) 2014-11-10
CL2013001793A1 (en) 2013-12-06
MX2013007588A (en) 2013-08-09
AR084610A1 (en) 2013-05-29
BR112013014875A2 (en) 2016-10-18
SG190905A1 (en) 2013-07-31
EP2658530A2 (en) 2013-11-06
AU2011350396A1 (en) 2013-07-11
EA028217B1 (en) 2017-10-31
CN103402500A (en) 2013-11-20
JP2014501224A (en) 2014-01-20
CA2823166C (en) 2019-04-09
MA34768B1 (en) 2013-12-03
CA2823166A1 (en) 2012-07-05
CO6731132A2 (en) 2013-08-15
US20130273157A1 (en) 2013-10-17
UY33841A (en) 2012-07-31
KR20140007364A (en) 2014-01-17
PE20141115A1 (en) 2014-09-12
TW201304823A (en) 2013-02-01
EA201390981A1 (en) 2014-07-30
ZA201304617B (en) 2014-08-27
CR20130327A (en) 2013-08-22
WO2012091153A2 (en) 2012-07-05
ECSP13012718A (en) 2013-12-31
SG10201602311XA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
WO2012091153A3 (en) Orally disintegrating tablet
MX2022002952A (en) Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phen oxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]- 4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.
RU2337687C2 (en) Pharmaceutical composition of controlled release and method of production thereof
JP2010270128A5 (en)
JP2019147832A5 (en)
CA2797812A1 (en) Enteric tablet
NZ591688A (en) Dosage form comprising time-pulsatile release beads
RU2015110824A (en) PHARMACEUTICAL OR NUTRICEVITIC COMPOSITION WITH SLOW DELIVERY AND RESISTANCE TO ETHANOL
JP2013522219A5 (en)
WO2006049564A8 (en) New modified release pellet formulations for proton pump inhibitors
JP2012518655A5 (en)
RU2015110825A (en) RESISTANT TO ACTION OF THE GASTRIC JUICE PHARMACEUTICAL OR NUTRICEUTIC COMPOSITION RESISTANT TO THE INFLUENCE OF ETHANOL
AU2007276874A1 (en) Granular pharmaceutical compositions
MX2007004987A (en) New modified release tablet formulations for proton pump inhibitors.
RU2014131238A (en) COMPOSITION WITH DELAYED RELEASE TO REDUCE THE URINE FREQUENCY AND METHOD OF ITS APPLICATION
JP2017537168A5 (en)
RU2012136839A (en) COMPOSITIONS FOR CARE OF THE ORAL CAVITY AND REMOVAL OF AN UNFAMING ODOR
CN103338774A (en) Orally disintegrating tablet
JP2014533656A5 (en)
JP2013529637A5 (en)
EP2641594B1 (en) Enteric coated solid pharmaceutical compositions for proton pump inhibitors
WO2014086857A1 (en) Oral pharmaceutical composition comprising dabigatran etexilate
CA2797809A1 (en) Enteric tablet
CA2733299A1 (en) Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
CN103751137A (en) Multi-cell ranolazine slow-release pellet tablet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811174

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 226590

Country of ref document: IL

REEP Request for entry into the european phase

Ref document number: 2011811174

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011811174

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 0184013

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2013001793

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 13997862

Country of ref document: US

Ref document number: 001471-2013

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2823166

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12013501391

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2013529237

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/007588

Country of ref document: MX

Ref document number: CR2013-000327

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2011350396

Country of ref document: AU

Date of ref document: 20111226

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13173

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 20137019795

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13176405

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201309398

Country of ref document: UA

Ref document number: 201390981

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013014875

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013014875

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130613